A placebo-controlled clinical trial for topical diacerein 1% (Castle Creek Pharmaceuticals) in the treatment of epidermolysis bullosa simplex (EBS) demonstrated the investigational ointment provides sustainable long-term benefit in reduction of blister formation in EBS, according to results presented in a late-breaking research session at the American Academy of Dermatology Annual Meeting in Orlando. The ointment is a potentially disease-modifying therapy that blocks an important inflammatory signaling pathway in EBS.
Professor Johann Bauer, MD, MBA, HCM, head of the University Clinic for Dermatology at the SALK/Paracelsus Medical University and principal investigator in the trial, presented the results of the multicenter, randomized, double-blind, placebo-controlled phase 2 trial that included 17 patients with EBS who were treated for 4 weeks followed by 3-month follow-up and subsequent cross-over in year 2. Previously reported results showed a 60%reduction in blistering among patients treated with diacerein 1% versus a 15% reduction in the placebo group at 4 weeks. At 3 months, 67% of patients in the placebo group returned to baseline blistering levels, versus 12.5% of patients in the diacerein 1% treatment group. Topical diacerein 1% was well tolerated with no treatment-related adverse events reported.
“With no treatment options available, management of EBS remains a significant area of unmet need in health care. These results represent a historic advance in research related to EBS indicating the potential to bring patients a safe and effective treatment option in the years ahead,” said Dr Bauer. “Importantly, these results also show the potential for diacerein 1% to offer long-term benefits in patients experiencing blistering associated with EBS.”
EBS is the most common form of epidermolysis bullosa, a rare dermatologic condition where patients have a genetic defect that compromises the structural integrity of their skin, making it particularly fragile and prone to blistering over their entire bodies. Severe cases of EBS involve widespread blistering that can lead to infections, dehydration, and other medical problems.
A placebo-controlled clinical trial for topical diacerein 1% (Castle Creek Pharmaceuticals) in the treatment of epidermolysis bullosa simplex (EBS) demonstrated the investigational ointment provides sustainable long-term benefit in reduction of blister formation in EBS, according to results presented in a late-breaking research session at the American Academy of Dermatology Annual Meeting in Orlando. The ointment is a potentially disease-modifying therapy that blocks an important inflammatory signaling pathway in EBS.
Professor Johann Bauer, MD, MBA, HCM, head of the University Clinic for Dermatology at the SALK/Paracelsus Medical University and principal investigator in the trial, presented the results of the multicenter, randomized, double-blind, placebo-controlled phase 2 trial that included 17 patients with EBS who were treated for 4 weeks followed by 3-month follow-up and subsequent cross-over in year 2. Previously reported results showed a 60%reduction in blistering among patients treated with diacerein 1% versus a 15% reduction in the placebo group at 4 weeks. At 3 months, 67% of patients in the placebo group returned to baseline blistering levels, versus 12.5% of patients in the diacerein 1% treatment group. Topical diacerein 1% was well tolerated with no treatment-related adverse events reported.
“With no treatment options available, management of EBS remains a significant area of unmet need in health care. These results represent a historic advance in research related to EBS indicating the potential to bring patients a safe and effective treatment option in the years ahead,” said Dr Bauer. “Importantly, these results also show the potential for diacerein 1% to offer long-term benefits in patients experiencing blistering associated with EBS.”
EBS is the most common form of epidermolysis bullosa, a rare dermatologic condition where patients have a genetic defect that compromises the structural integrity of their skin, making it particularly fragile and prone to blistering over their entire bodies. Severe cases of EBS involve widespread blistering that can lead to infections, dehydration, and other medical problems.
A placebo-controlled clinical trial for topical diacerein 1% (Castle Creek Pharmaceuticals) in the treatment of epidermolysis bullosa simplex (EBS) demonstrated the investigational ointment provides sustainable long-term benefit in reduction of blister formation in EBS, according to results presented in a late-breaking research session at the American Academy of Dermatology Annual Meeting in Orlando. The ointment is a potentially disease-modifying therapy that blocks an important inflammatory signaling pathway in EBS.
Professor Johann Bauer, MD, MBA, HCM, head of the University Clinic for Dermatology at the SALK/Paracelsus Medical University and principal investigator in the trial, presented the results of the multicenter, randomized, double-blind, placebo-controlled phase 2 trial that included 17 patients with EBS who were treated for 4 weeks followed by 3-month follow-up and subsequent cross-over in year 2. Previously reported results showed a 60%reduction in blistering among patients treated with diacerein 1% versus a 15% reduction in the placebo group at 4 weeks. At 3 months, 67% of patients in the placebo group returned to baseline blistering levels, versus 12.5% of patients in the diacerein 1% treatment group. Topical diacerein 1% was well tolerated with no treatment-related adverse events reported.
“With no treatment options available, management of EBS remains a significant area of unmet need in health care. These results represent a historic advance in research related to EBS indicating the potential to bring patients a safe and effective treatment option in the years ahead,” said Dr Bauer. “Importantly, these results also show the potential for diacerein 1% to offer long-term benefits in patients experiencing blistering associated with EBS.”
EBS is the most common form of epidermolysis bullosa, a rare dermatologic condition where patients have a genetic defect that compromises the structural integrity of their skin, making it particularly fragile and prone to blistering over their entire bodies. Severe cases of EBS involve widespread blistering that can lead to infections, dehydration, and other medical problems.
